IXICO is awarded multiple Alzheimer’s disease contracts

IXICO plc, the data analytics company delivering insights in neuroscience, announces that it has secured new contracts in Alzheimer’s disease (AD) clinical trials.

The new contracts include a Phase I study in Alzheimer’s disease with a new biotechnology customer, an expansion contract for a Phase II trial with an existing biotechnology company and the initiation of an open-label extension phase III trial with an existing large pharmaceutical company.

The contracts build on the strength IXICO has in AD clinical trials and are in addition to the partnership with the Global Alzheimer’s Platform which the Company announced on World Alzheimer’s Day, 21 September 2020.

These contracts were included in management's expectations of performance for the coming year and contribute to the Company's strong order book. These contracts relate to trials at different stages of drug development and are with several different customers, strengthening diversification in the Company’s order book.

Lammert Albers, Chief Commercial Officer of IXICO, commented: "Today there are 50 million people worldwide that suffer with Alzheimer’s and other forms of dementias. There are currently no means to prevent or delay onset, slow progression or meaningfully improve symptoms of Alzheimer’s disease. With more than 120 unique investigational drugs in clinical trials, IXICO is proud to support some of these potential treatments that one day may be in the hands of Alzheimer’s patients worldwide.

 

For further information please contact:

IXICO plc

+44 (0)20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 


Date: 03/11/2020